Contact Informatie voor patiƫnten Enrolment new DCCG study Menu

ASPIRIN trial

Acronym

ASPIRIN trial

Name of the study

A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

Researchers and contact information

Datacenter Department of Surgery
Leiden University Medical Center
Postzone K-6-R | P.O. Box 9600 | 2300 RC LEIDEN
The Netherlands
Tel +3171 526 3500 | Fax +3171 526 6744
E-mail datacenter@lumc.nl
Contact person: Jeffrey Braak

Summary study

Rationale: Preclinical, epidemiologic and clinical evidence suggest that acetylsalicylic acid use may reduce overall cancer risk and mortality in colon cancer patients.



Objective: To investigate acetylsalicylic acid 80 mg po daily for 5 years as an adjuvant therapy in curatively operated, stage II and III colon cancer patients.



Study design: A phase III double-blind placebo-controlled randomised trial of adjuvant low-dose acetylsalicylic acid in colon cancer patients. The question will be addressed by means of two parallel studies in patients treated with or without adjuvant chemotherapy.


Trial website:

www.aspirinagainstcancer.org

Intervention

Documents